154 related articles for article (PubMed ID: 24317126)
1. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).
Gossai N; Verneris MR; Karras NA; Gorman MF; Patel NJ; Burke MJ
Bone Marrow Transplant; 2014 Mar; 49(3):440-2. PubMed ID: 24317126
[TBL] [Abstract][Full Text] [Related]
2. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
Liu AP; Lee V; Li CK; Ha SY; Chiang AK
Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
[TBL] [Abstract][Full Text] [Related]
3. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
[TBL] [Abstract][Full Text] [Related]
6. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
8. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
Locke F; Agarwal R; Kunnavakkam R; van Besien K; Larson RA; Odenike O; Godley LA; Liu H; Le Beau MM; Gurbuxani S; Thirman MJ; Sipkins D; White C; Artz A; Stock W
Bone Marrow Transplant; 2013 Nov; 48(11):1437-43. PubMed ID: 23771005
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
10. [Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia].
Arakawa Y; Koh K; Aoki T; Kubota Y; Oyama R; Mori M; Hayashi M; Hanada R
Rinsho Ketsueki; 2014 Nov; 55(11):2316-9. PubMed ID: 25501414
[TBL] [Abstract][Full Text] [Related]
11. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
McGregor BA; Brown AW; Osswald MB; Savona MR
Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
[TBL] [Abstract][Full Text] [Related]
12. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
13. The combination of clofarabine, etoposide, and cyclophosphamide shows limited efficacy as a bridge to transplant for children with refractory acute leukemia: results of a monitored prospective study.
Toporski J; Król L; Dykes J; Håkansson Y; Pronk C; Turkiewicz D
Pediatr Hematol Oncol; 2021 Apr; 38(3):216-226. PubMed ID: 33150834
[TBL] [Abstract][Full Text] [Related]
14. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.
Messinger Y; Boklan J; Goldberg J; DuBois SG; Oesterheld J; Abla O; Martin A; Weinstein J; Hijiya N
Pediatr Hematol Oncol; 2017 May; 34(4):187-198. PubMed ID: 29039989
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
17. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
Saito T; Hatta Y; Hayakawa F; Takahashi T; Hagihara M; Iida H; Minauchi K; Yamazaki E; Sugiura I; Murayama T; Sakura T; Mori N; Imai K; Yahagi Y; Atsuta Y; Saito AM; Hirakawa A; Kiyoi H; Matsumura I; Miyazaki Y;
Int J Hematol; 2021 Mar; 113(3):395-403. PubMed ID: 33230647
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.
Soni S; Abdel-Azim H; McManus M; Nemecek E; Sposto R; Woolfrey A; Frangoul H
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1134-1141. PubMed ID: 28396162
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Zeidan AM; Ricklis RM; Carraway HE; Yun HD; Greer JM; Smith BD; Levis MJ; McDevitt MA; Pratz KW; Showel MM; Gladstone DE; Gore SD; Karp JE
Br J Haematol; 2012 Jul; 158(2):198-207. PubMed ID: 22594769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
